Daiichi seeking denosumab approval in Japan

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) submitted an MAA for denosumab ( AMG 162) in Japan to treat bone disorders stemming from bone metastases. The human mAb targeting receptor activator of...